Novel methods for tracking long-term maintenance immunosuppression regimens.
OBJECTIVE
Accurate assessment of the use of immunosuppressive medications is vital for observational analyses that are widely used in transplantation research. This study assessed the accuracy of three potential sources of maintenance immunosuppression data.


METHODS
This study investigated the agreement of immunosuppression information in directly linked electronic medical records for Medicare beneficiaries who received a kidney transplant at one center in 1998 through 2001, Organ Procurement and Transplantation Network (OPTN) survey data, and Medicare pharmacy claims. Pair-wise, interdata concordance (kappa) and percentage agreement statistics were used to compare immunosuppression regimens reported at discharge, and at 6 mo and 1 yr after transplantation in each data source.


RESULTS
Among 181 eligible participants, agreement between data sources for nonsteroid immunosuppression increased with time after transplantation. By 1-yr, concordance was excellent for calcineurin inhibitors and mycophenolate mofetil (kappa = 0.79 to 1.00), and very good for azathioprine (kappa = 0.73 to 0.85). Similarly, percentage agreement at 1 yr was 94.9 to 100% for calcineurin inhibitors, 91.1 to 95.7% for mycophenolate mofetil, and 87.5 to 92.8% for azathioprine. Widening the comparison time window resolved 33.6% of cases with discordant indications of calcineurin inhibitor and/or antimetabolite use in claims compared with other data sources.


CONCLUSIONS
This analysis supports the accuracy of the three sources of data for description of nonsteroid immunosuppression after kidney transplantation. Given the current strategic focus on reducing collection of data, use of alternative measures of immunosuppression exposure is appropriate and will assume greater importance.
Buchanan
Paula M
PM
Center for Outcomes Research, St. Louis University School of Medicine, St. Louis, Missouri, USA.
Schnitzler
Mark A
MA
Brennan
Daniel C
DC
Dzebisashvili
Nino
N
Willoughby
Lisa M
LM
Axelrod
David
D
Salvalaggio
Paolo R
PR
Abbott
Kevin C
KC
Burroughs
Thomas E
TE
Lentine
Krista L
KL
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003625:Data Collection / Q000379:methods; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000706:statistics & numerical data*; D016347:Medical Records Systems, Computerized / Q000706:statistics & numerical data*; D006278:Medicare / Q000706:statistics & numerical data*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010594:Pharmacies / Q000706:statistics & numerical data*; D015995:Prevalence; D020123:Sirolimus / Q000627:therapeutic use; D009927:Tissue and Organ Procurement / Q000706:statistics & numerical data; D014481:United States / Q000453:epidemiology
D000305:Adrenal Cortex Hormones; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D020123:Sirolimus